Charlson comorbidity index is an important prognostic factor for long-term survival outcomes in Korean men with prostate cancer after radical prostatectomy

Yonsei Medical Journal

Volumn 55, Issue 2, 2014, Pages 316-323

  Lee, Joo Yong ^a   Lee, Dae Hun ^b   Cho, Nam Hoon ^a   Rha, Koon Ho ^a   Choi, Young Deuk ^a   Hong, Sung Joon ^a   Yang, Seung Choul ^a   Cho, Kang Su ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Comorbidity; Prostatic neoplasms; Survival

Indexed keywords

COMORBIDITY; PROSTATIC NEOPLASMS; SURVIVAL;

AGED; COMORBIDITY; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATECTOMY; PROSTATIC NEOPLASMS; REPUBLIC OF KOREA; SURVIVAL RATE;

EID: 84894282962     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2014.55.2.316     Document Type: Article

References (34)

1. Tewari A, Sooriakumaran P, Bloch DA, Seshadri-Kreaden U, Hebert AE, Wiklund P. Positive surgical margin and perioperative complication rates of primary surgical treatments for prostate cancer: a systematic review and meta-analysis comparing retropubic, laparoscopic, and robotic prostatectomy. Eur Urol 2012;62:1-15.
2. Schröder FH, Carter HB, Wolters T, van den Bergh RC, Gosselaar C, Bangma CH, et al. Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics. Eur Urol 2008;53:468-77.
3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
4. Yun SJ, Min BD, Kang HW, Shin KS, Kim TH, Kim WT, et al. Elevated insulin and insulin resistance are associated with the advanced pathological stage of prostate cancer in Korean population. J Korean Med Sci 2012;27:1079-84.
5. Zhang YF, Guan YB, Yang B, Wu HY, Dai YT, Zhang SJ, et al. Prognostic value of Her-2/neu and clinicopathologic factors for evaluating progression and disease-specific death in Chinese men with prostate cancer. Chin Med J (Engl) 2011;124:4345-9.
6. Okada K, Okihara K, Kitamura K, Mikami K, Ukimura O, Kawauchi A, et al. Community-based prostate cancer screening in Japan: predicting factors for positive repeat biopsy. Int J Urol 2010;17:541-7.
7. Yoshida T, Nakayama M, Takeda K, Arai Y, Kakimoto K, Nishimura K. External validation of the cancer of the prostate risk assessment score to predict biochemical relapse after radical prostatectomy for prostate cancer in Japanese patients. Urol Int 2012;89:45-51.
8. Hyun JS. Prostate cancer and sexual function. World J Mens Health 2012;30:99-107.
9. Ro YK, Lee S, Jeong CW, Hong SK, Byun SS, Lee SE. Biochemical recurrence in Gleason score 7 prostate cancer in Korean men: significance of the primary Gleason grade. Korean J Urol 2012;53: 826-9.
10. Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008;358:1250-61.
11. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, et al. EAU guidelines on prostate cancer. Eur Urol 2008;53:68-80.
12. Mohler JL, Armstrong AJ, Bahnson RR, Boston B, Busby JE, D'Amico AV, et al. Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2012;10: 1081-7.
13. Wilson JR, Clarke MG, Ewings P, Graham JD, MacDonagh R. The assessment of patient life-expectancy: how accurate are urologists and oncologists? BJU Int 2005;95:794-8.
14. Froehner M, Koch R, Litz RJ, Hakenberg OW, Wirth MP. Which patients are at the highest risk of dying from competing causes 10 years after radical prostatectomy? BJU Int 2012;110:206-10.
15. Froehner M, Koch R, Litz RJ, Oehlschlaeger S, Hakenberg OW, Wirth MP. Feasibility and limitations of comorbidity measurement in patients undergoing radical prostatectomy. Eur Urol 2005;47: 190-5.
16. Froehner M, Koch R, Litz RJ, Hakenberg OW, Oehlschlaeger S, Wirth MP. Comorbidity is poor predictor of survival in patients undergoing radical prostatectomy after 70 years of age. Urology 2006;68:583-6.
17. Froehner M, Koch R, Litz RJ, Oehlschlaeger S, Twelker L, Hakenberg OW, et al. Detailed analysis of Charlson comorbidity score as predictor of mortality after radical prostatectomy. Urology 2008;72:1252-7.
18. Guzzo TJ, Dluzniewski P, Orosco R, Platz EA, Partin AW, Han M. Prediction of mortality after radical prostatectomy by Charlson comorbidity index. Urology 2010;76:553-7.
19. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Prev Med 2007;45:247-51.
20. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol 1993;46:1075-9.
21. Heagerty PJ, Zheng Y. Survival model predictive accuracy and ROC curves. Biometrics 2005;61:92-105.
22. Albertsen PC, Moore DF, Shih W, Lin Y, Li H, Lu-Yao GL. Impact of comorbidity on survival among men with localized prostate cancer. J Clin Oncol 2011;29:1335-41.
23. Post PN, Hansen BE, Kil PJ, Janssen-Heijnen ML, Coebergh JW. The independent prognostic value of comorbidity among men aged 75 years with localized prostate cancer: a population-based study. BJU Int 2001;87:821-6.
24. Lund L, Borre M, Jacobsen J, Sørensen HT, Nørgaard M. Impact of comorbidity on survival of Danish prostate cancer patients, 1995-2006: a population-based cohort study. Urology 2008;72: 1258-62.
25. Briganti A, Spahn M, Joniau S, Gontero P, Bianchi M, Kneitz B, et al. Impact of age and comorbidities on long-term survival of patients with high-risk prostate cancer treated with radical prostatectomy: a multi-institutional competing-risks analysis. Eur Urol 2013;63:693-701.
26. Daskivich TJ, Chamie K, Kwan L, Labo J, Dash A, Greenfield S, et al. Comorbidity and competing risks for mortality in men with prostate cancer. Cancer 2011;117:4642-50.
27. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005;293:2095-101.
28. Hsu CY, Joniau S, Oyen R, Roskams T, Van Poppel H. Correlations between age, Charlson score and outcome in clinical unilateral T3a prostate cancer. Asian J Androl 2009;11:131-7.
29. Singh GK, Miller BA. Health, life expectancy, and mortality patterns among immigrant populations in the United States. Can J Public Health 2004;95:I14-21.
30. Ebrahim S, Patel N, Coats M, Greig C, Gilley J, Bangham C, et al. Prevalence and severity of morbidity among Gujarati Asian elders: a controlled comparison. Fam Pract 1991;8:57-62.
31. Woo EK, Han C, Jo SA, Park MK, Kim S, Kim E, et al. Morbidity and related factors among elderly people in South Korea: results from the Ansan Geriatric (AGE) cohort study. BMC Public Health 2007;7:10.
32. Lim S, Park KS, Lee HK, Cho SI. Changes in the characteristics of metabolic syndrome in Korea over the period 1998-2001 as determined by Korean National Health and Nutrition Examination Surveys. Diabetes Care 2005;28:1810-2.
33. Byun SS, Lee S, Lee SE, Lee E, Seo SI, Lee HM, et al. Recent changes in the clinicopathologic features of Korean men with prostate cancer: a comparison with Western populations. Yonsei Med J 2012;53:543-9.
34. Kil SR, Lee SI, Khang YH, Lee MS, Kim HJ, Kim SO, et al. Development and validation of comorbidity index in South Korea. Int J Qual Health Care 2012;24:391-402.